ProMIS Neurosciences Inc. reports clinical-stage biotechnology developments around antibody therapeutics and vaccines that target toxic misfolded proteins in neurodegenerative diseases. Company news centers on PMN310, its lead humanized monoclonal antibody for Alzheimer’s disease, the PRECISE-AD clinical program, FDA Fast Track designation, biomarker research involving plasma pTau, and scientific publications or conference presentations tied to Alzheimer’s disease, ALS, and Parkinson’s disease.
Updates also cover operating and financial results, governance matters, shareholder votes, capital-structure actions, and investor conference participation. The company’s research disclosures emphasize its proprietary discovery platform and selective targeting of disease-specific toxic protein species rather than broader amyloid plaque binding.
ProMIS Neurosciences (Nasdaq: PMN) reported 2025 results and corporate updates on March 25, 2026, highlighting clinical and financing milestones.
Key points: PRECISE-AD Phase 1b enrollment completed at 144 patients; six-month assessments due Q2 2026 with a blinded interim analysis expected early Q3 2026; top-line data anticipated early 2027. PMN310 shows a favorable safety profile with no treatment-related SAEs to date. The company closed gross up-front financing of $75.5M (part of up to $175M), providing runway through 2027.
ProMIS Neurosciences (Nasdaq: PMN) will present two scientific posters at the AD/PD™ 2026 conference in Copenhagen, March 17–21, 2026. Both posters, scheduled March 20, 2026, describe vaccine and antibody approaches targeting misfolded TDP‑43 and toxic alpha‑synuclein species for ALS and Parkinson’s disease.
Presenters include Neil Cashman and Johanne Kaplan; sessions cover mechanisms, translational strategies, and computationally derived conformational epitopes.
ProMIS Neurosciences (Nasdaq: PMN) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026 in New York. The company will host a fireside chat at 9:30 AM ET on February 11 and hold investor one-on-one meetings.
A live webcast of the fireside chat will be available via the company Events page at www.promisneurosciences.com and will remain accessible for at least 30 days after the event.
ProMIS Neurosciences (NASDAQ: PMN) entered a PIPE to raise up to $175 million via issuance of common shares, pre-funded warrants and common share warrants. Upfront gross proceeds are expected to be approximately $75 million, with up to an additional $100 million if warrants are fully exercised.
The financing is expected to close on February 3, 2026, extends cash runway into 2028, and is intended to fund completion of the Phase 1b Alzheimer’s study and subcutaneous formulation development. Blinded 6-month topline data are expected mid-2026 and 12-month topline data toward end of 2026.
ProMIS Neurosciences (NASDAQ: PMN) completed enrollment of 144 patients in the PRECISE-AD Phase 1b trial of PMN310 for early Alzheimer’s disease, exceeding its target. The randomized, double-blind, placebo-controlled 12-month study will assess safety, tolerability, pharmacokinetics, biomarkers, and clinical effects of an antibody selective for toxic soluble amyloid-beta oligomers.
To date PMN310 shows a favorable safety profile with limited discontinuations and no treatment-related serious adverse events. A blinded 6-month interim analysis is planned for Q2 2026 and final unblinded top-line results for Q4 2026.
ProMIS Neurosciences (Nasdaq: PMN) reported a peer‑reviewed publication linking clinical efficacy of Aβ antibodies to selective binding of soluble toxic Aβ oligomers. The study found PMN310 preserved oligomer binding despite high monomer concentrations, showed no detectable plaque or vascular binding, and produced no microhemorrhages in high‑dose, chronic plaque‑bearing mice. ProMIS said PRECISE‑AD enrollment is on track to finish by end of 2025, with a 6‑month interim readout planned for Q2 2026 and top‑line results expected in Q4 2026.
ProMIS Neurosciences (Nasdaq: PMN) announced a peer‑reviewed cross‑trial analysis showing plasma pTau181/217 as a potential early predictive endpoint in Alzheimer’s trials. The analysis reported a strong group‑level correlation (≈ 0.78) between 6‑month plasma pTau changes and 12‑month CDR‑SB outcomes, an effect size on plasma pTau ~2.6× larger than clinical change, and simulations indicating well‑powered POC trials could require ~100 participants. ProMIS says these findings align with PRECISE‑AD’s biomarker‑centric design and support a planned blinded 6‑month biomarker readout, including pTau217, expected in Q2 2026.
ProMIS Neurosciences (Nasdaq: PMN) announced that CEO Neil Warma will speak at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The appearance includes a fireside chat at 3:25 PM ET and investor one-on-one meetings.
A live webcast of the presentation will be available via the company Events page at www.promisneurosciences.com and will remain accessible for at least 30 days after the event.
ProMIS Neurosciences (Nasdaq: PMN) will effect a one-for-twenty-five reverse stock split of its common shares at 12:01 a.m. ET on November 28, 2025. The split will reduce outstanding shares from approximately 53,811,110 to approximately 2,152,444 and a new CUSIP 74346M505 will be assigned.
Proportional adjustments will be made to equity awards, options, warrants and exercise prices; fractional shares will be settled in cash. The board says the split is intended to increase the market price and cure a Nasdaq bid-price deficiency; Nasdaq extended the company’s compliance period to December 29, 2025.
ProMIS Neurosciences (Nasdaq: PMN) reported Q3 2025 results and corporate updates on Nov 12, 2025. The company said its Phase 1b PRECISE-AD trial of PMN310 is over 85% enrolled, with Cohorts 1 and 2 fully enrolled and Cohort 3 expected to complete enrollment before year-end.
PMN310 continues to show a favorable safety profile; the DSMB cleared progression to the third dose cohort. ProMIS expects 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026. Cash was $15.4M at Sept 30, 2025, after July financing that generated ~$21.6M gross proceeds. Q3 R&D expense was $9.8M (Q3 2024: $2.6M); operating loss was $11.8M (Q3 2024: $4.4M).